In the big drug makers' struggle with generic producers, billions are at stake. To defend their turf and patents, companies employ numerous tactics, some of them questionable. Earlier in July, a group of drugstore chains filed a federal antitrust suit in Miami against Abbott Laboratories, Zenith Goldline Pharmaceuticals Inc. and Geneva Pharmaceuticals, alleging that Abbott signed "unlawful agreements" with Zenith and Geneva and paid them not to market a generic version of Abbott's high blood pressure drug.
July 29, 1999 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
A huge pharmaceuticals company pays a smaller rival millions not tosell a generic version of the drug giant’s product.Is it a smart business deal, or an illicit ploy to restraincompetition?
That’s one of the questions increasingly being asked as the powerfulbrand-name prescription drug industry fights to protect its profitsfrom smaller, generic drug makers vying to cash in by offering cheaperversions of popular drugs.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
